Monopar Therapeutics (NASDAQ:MNPR) Reaches New 12-Month High – Here’s What Happened

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $115.00 and last traded at $111.2940, with a volume of 10976 shares changing hands. The stock had previously closed at $111.12.

Analyst Ratings Changes

MNPR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $105.00 target price on shares of Monopar Therapeutics in a research note on Monday, June 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research report on Tuesday, June 2nd. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Stock Up 7.2%

The firm has a market capitalization of $760.81 million, a price-to-earnings ratio of -59.77 and a beta of 1.46. The business’s 50-day simple moving average is $77.57 and its two-hundred day simple moving average is $65.75.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.41. Sell-side analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently modified their holdings of the company. Wellington Management Group LLP purchased a new position in Monopar Therapeutics during the 3rd quarter valued at about $18,904,000. Siren L.L.C. purchased a new stake in Monopar Therapeutics during the fourth quarter worth about $13,863,000. Deerfield Management Company L.P. purchased a new stake in Monopar Therapeutics during the third quarter worth about $13,048,000. RA Capital Management L.P. lifted its position in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after purchasing an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC acquired a new stake in shares of Monopar Therapeutics during the third quarter worth about $12,496,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.